Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy. Issue 2 (21st May 2018)
- Record Type:
- Journal Article
- Title:
- Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy. Issue 2 (21st May 2018)
- Main Title:
- Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy
- Authors:
- Hao, Ying
Chen, YuWen
Lei, MinYi
Zhang, TaoYe
Cao, YiPing
Peng, JinRong
Chen, LiJuan
Qian, ZhiYong - Abstract:
- Abstract: Currently, epidermoid cancer is one of the most common malignancies among Caucasians. Traditional treatment may yield uncomfortable side effects for the patient. In order to solve these problems, the authors develop a near‐infrared (NIR) responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) for human epidermoid cancer therapy. The as‐made GNR‐PEG&DOX@HA MNs has good skin penetration capability and heating ability. The heating can be transferred to the center of the tumor sites and the temperature is shown to rise up to 60 °C within 5 min. Meanwhile, the release behavior of the DOX from GNR‐PEG&DOX@HA MNs can be controlled by NIR light. The GNR‐PEG&DOX@HA MNs shows good cell inhibition, and the photothermal effect is shown to completely destroy A431 cells in vitro. For in vivo antitumor study, the group treated with GNR‐PEG&DOX@HA MNs transcutaneously reveals a remarkable antitumor efficacy, such that all mice are cured without recurrence under only one treatment. Hence, this novel transdermal drug delivery strategy offers hope to human epidermoid cancer therapy, and GNR‐PEG&DOX@HA MN may serve as a promising candidate in clinical translation for human epidermoid cancer therapy. Abstract : A synergetic system of chemotherapy and PTT via the combination of a near‐infrared (NIR) light responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acidAbstract: Currently, epidermoid cancer is one of the most common malignancies among Caucasians. Traditional treatment may yield uncomfortable side effects for the patient. In order to solve these problems, the authors develop a near‐infrared (NIR) responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) for human epidermoid cancer therapy. The as‐made GNR‐PEG&DOX@HA MNs has good skin penetration capability and heating ability. The heating can be transferred to the center of the tumor sites and the temperature is shown to rise up to 60 °C within 5 min. Meanwhile, the release behavior of the DOX from GNR‐PEG&DOX@HA MNs can be controlled by NIR light. The GNR‐PEG&DOX@HA MNs shows good cell inhibition, and the photothermal effect is shown to completely destroy A431 cells in vitro. For in vivo antitumor study, the group treated with GNR‐PEG&DOX@HA MNs transcutaneously reveals a remarkable antitumor efficacy, such that all mice are cured without recurrence under only one treatment. Hence, this novel transdermal drug delivery strategy offers hope to human epidermoid cancer therapy, and GNR‐PEG&DOX@HA MN may serve as a promising candidate in clinical translation for human epidermoid cancer therapy. Abstract : A synergetic system of chemotherapy and PTT via the combination of a near‐infrared (NIR) light responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) is developed for human epidermoid cancer therapy. The GNR‐PEG&DOX@HA MNs efficiently inhibit the tumor growth with only one treatment and cure all mice without any recurrence. … (more)
- Is Part Of:
- Advanced therapeutics. Volume 1:Issue 2(2018)
- Journal:
- Advanced therapeutics
- Issue:
- Volume 1:Issue 2(2018)
- Issue Display:
- Volume 1, Issue 2 (2018)
- Year:
- 2018
- Volume:
- 1
- Issue:
- 2
- Issue Sort Value:
- 2018-0001-0002-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2018-05-21
- Subjects:
- doxorubicin (DOX) -- GNR‐PEG&DOX@HA MNs -- human epidermoid cancer -- hyaluronic acid (HA) -- PEGylated gold nanorod (GNR‐PEG)
Therapeutics -- Periodicals
Pharmaceutical technology -- Periodicals
Pharmacogenetics -- Periodicals
615.5 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/23663987 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/adtp.201800008 ↗
- Languages:
- English
- ISSNs:
- 2366-3987
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0696.935580
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 6967.xml